KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q3 2025 value amounting to $4.5 million.

  • Vertex Pharmaceuticals' Treasury Shares rose 16470.59% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 16470.59%. This contributed to the annual value of $2.7 million for FY2024, which is 884.54% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Treasury Shares stood at $4.5 million for Q3 2025, which was up 16470.59% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Treasury Shares peaked at $7.3 million during Q4 2021, and registered a low of $300000.0 during Q1 2024.
  • Its 5-year average for Treasury Shares is $2.3 million, with a median of $1.9 million in 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Treasury Shares skyrocketed by 20416.67% in 2021 and then crashed by 6009.59% in 2022.
  • Over the past 5 years, Vertex Pharmaceuticals' Treasury Shares (Quarter) stood at $7.3 million in 2021, then plummeted by 60.1% to $2.9 million in 2022, then rose by 1.68% to $3.0 million in 2023, then fell by 8.85% to $2.7 million in 2024, then skyrocketed by 66.67% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $1.8 million for Q2 2025, and $900000.0 during Q1 2025.